"rationale","name","instanceType","label","uuid:ID","id","description"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign","","ca5c600d-a25d-45ea-be22-ec64e4a842ed","StudyDesign_1","The main design for the study"
